Create Compliance Culture (and Improve Regulatory-Marketing Relationships) with Colleen Hittle, CEO, ProVeritas Partners #messageengineer #medtech

Create Compliance Culture (and Improve Regulatory-Marketing Relationships) with Colleen Hittle, CEO, Proveritas Partners! Colleen Hittle, CEO, ProVeritas Partners, joins Maureen Shaffer, CEO, Mingletoe, to chat about the sometimes challenging relationship between marketing and regulatory / compliance / legal and how to solve for synergy. Colleen also shared her thoughts on common startup compliance mistakes and how medtech startups can be smarter upfront about risk management.

🎬 WATCH this video episode https://youtu.be/p3FaPmMf4NQ

🎬 WATCH all video episodes https://www.youtube.com/@messageengineer

🎙 LISTEN to the full episode on the Message Engineer Podcast everywhere! Including Apple Podcast, Audible, Spotify, and iHeartRadio. If you are a fan of “Alexa”, try “Alexa, play Message Engineer podcast” on any Amazon Echo product.

Key takeaways include: 

• Why marketing must involve regulatory / compliance / legal in the creative process
• Uncommon tips for regulatory / compliance / legal to work better with marketing
• Common startup compliance and design control mistakes that cost more money later
• Strategic ways startups can build the regulatory function for success
• How regulatory and marketing can educate each other, and much more!

🚀 Want help with your message strategy? DM me on LinkedIn!

About Colleen Hittle

Colleen Hittle has more than 25 years of experience in the healthcare and life sciences regulatory environment, providing technical and expert support to companies regulated by the U.S. Food and Drug Administration (FDA) as well as international, global regulatory bodies. Colleen has been accepted as expert in multiple jurisdictions in matters related to transactions, disputes and litigation in healthcare and life sciences industry.

Colleen has led global regulatory and compliance services teams, providing support for companies developing and marketing products in the medical device, health information technology, combination product, and drug and biologics industries. Former President, CEO, and owner of Anson Group (an FDA regulatory consultancy acquired by a publicly traded firm in 2013), Colleen has served FDA-regulated companies ranging from the smallest start-ups to Fortune 20 industry leaders.

A highly sought-after Strategic Advisor for mergers and acquisitions, she led regulatory, quality system, and compliance diligence reviews for deals with a total value of $25B over a three-year time period. She has testified as an expert witness at FDA hearings and meetings and in civil litigation matters; led a multi-site investigation of allegations of compliance record falsification; provided primary leadership on engagements to